LOW FIXED-DOSE HYDROXYUREA IN SEVERELY AFFECTED INDIAN CHILDREN WITH SICKLE CELL DISEASE

被引:33
作者
Jain, Dipty L. [1 ]
Sarathi, Vijaya [1 ]
Desai, Saumil [1 ]
Bhatnagar, Manoj [1 ]
Lodha, Abhijit [1 ]
机构
[1] Govt Med Coll, Dept Paediat, Nagpur 440009, Maharashtra, India
关键词
Hydroxyurea (HU); Sickle cell disease; Vasoocclusive crises; Blood transfusions; Hospitalizations; FETAL-HEMOGLOBIN; SPLENIC FUNCTION; ANEMIA; EFFICACY; THERAPY;
D O I
10.3109/03630269.2012.697948
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is limited data on the efficacy of hydroxyurea (HU) in Indian sickle cell anemia patients who have severe manifestations despite high fetal hemoglobin (Hb F). Sixty sickle cell anemia children (5-18 years) with more than three episodes of vasoocclusive crises or blood transfusions per year were randomized to receive HU (n = 30) or placebo (n = 30) therapy. Fixed dose (10 mg/kg/day) of HU was administered for 18 months and the patients were followed-up monthly with clinical assessment and laboratory monitoring. In the HU group, hemoglobin (Hb) and Hb F levels increased significantly along with a significant decrease in the number of painful crises, blood transfusion requirements and hospitalizations compared to the placebo group. No major adverse events were observed in this study. In conclusion, low-fixed dose HU therapy was effective for the treatment of Indian sickle cell anemia children. However, there is a need for long-term studies to evaluate the efficacy and toxicity in a larger number of Indian sickle cell anemia patients.
引用
收藏
页码:323 / 332
页数:10
相关论文
共 25 条
[1]  
ALCAIN FJ, 1994, BIOCHEM MOL BIOL INT, V34, P273
[2]   Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase [J].
Cokic, VP ;
Smith, RD ;
Beleslin-Cokic, BB ;
Njoroge, JM ;
Miller, JL ;
Gladwin, MT ;
Schechter, AN .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (02) :231-239
[3]   EFFECT OF HYDROXYUREA ON RIBONUCLEOTIDE REDUCTASE [J].
ELFORD, HL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1968, 33 (01) :129-+
[4]   Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study [J].
Hankins, JS ;
Ware, RE ;
Rogers, ZR ;
Wynn, LW ;
Lane, PA ;
Scott, JP ;
Wang, WC .
BLOOD, 2005, 106 (07) :2269-2275
[5]   Rat liver-mediated metabolism of hydroxyurea to nitric oxide [J].
Huang, Jinming ;
Yakubu, Mamudu ;
Kim-Shapiro, Daniel B. ;
King, S. Bruce .
FREE RADICAL BIOLOGY AND MEDICINE, 2006, 40 (09) :1675-1681
[6]   Hydroxyurea in sickle cell disease-A study of clinico-pharmacological efficacy in the Indian haplotype [J].
Italia, Khushnooma ;
Jain, Dipty ;
Gattani, Sushma ;
Jijina, Farah ;
Nadkarni, Anita ;
Sawant, Pratibha ;
Nair, Sona ;
Mohanty, Dipika ;
Ghosh, Kanjaksha ;
Colah, Roshan .
BLOOD CELLS MOLECULES AND DISEASES, 2009, 42 (01) :25-31
[7]  
Kinney TR, 1999, BLOOD, V94, P1550
[8]   A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger [J].
Mabaera, Rodwell ;
West, Rachel J. ;
Conine, Sarah J. ;
Macari, Elizabeth R. ;
Boyd, Chelsea D. ;
Engman, Cocav A. ;
Lowrey, Christopher H. .
EXPERIMENTAL HEMATOLOGY, 2008, 36 (09) :1057-1072
[9]   Sickle cell disease in India [J].
Mohanty, D ;
Mukherjee, MB .
CURRENT OPINION IN HEMATOLOGY, 2002, 9 (02) :117-122
[10]  
Mukherjee MB, 1997, AM J HEMATOL, V55, P104, DOI 10.1002/(SICI)1096-8652(199706)55:2<104::AID-AJH9>3.0.CO